fda stanc look like posit iqo
believ altria deliv double-digit ep growth next three year
long-term growth target driven price tax save manag spend abi
equiti incom growth share buyback fall interest expens consid
growth attract especi dividend yield remain bullish prospect
fda approv iqo especi light bat neocor approv maintain
ep trim ep keep price target
fda put money mouth see posit read iqo
bat se approv neocor eclips product believ reflect
import fda provid non-combust altern consum
process remain slow time uncertain still expect iqo approv
launch us like sometim year iqo typic tobacco flavor tobacco
menthol tobacco aerosol sourc believ increas
appeal smoker decreas youth posit regulatori prospect
rais volum outlook prefer conserv stanc volum
outlook given high fuel price state excis tax increas detail vapor
competit still see modest upsid rais volum outlook
outlook altria volum fell ex-
trade de-load estim underli declin
inventori recoveri extra ship day
state tax hike vapor factor categori outlook april california
tax hike headwind us volum kentucki
oklahoma rais tax juli two state combin us
volum potenti ad us volum headwind alreadi includ
estim also continu monitor vapor impact cigarett
smokeless tobacco typic cigarett categori declin reflect switch
product vapor may intercept switcher may use moist snuff otherwis
iqo help support long-term bullish outlook iqo get approv
us launch expect altria built least three iqo launch scenario
allow scale need lead market depend consum respons
price market approach etc still subject test market result time
iqo market author potenti reduc risk claim unknown
manag readi launch soon author given pack product
ship clear custom get shelf like take month
unfavor regul disrupt excis tax hike gain illicit trade risk profit
altria commerci tobacco product us brand like marlboro skoal
price close juli
price target
ep current multipl
ep expect altria deliv
three-year averag sale growth
revenu exclud excis tax
piper jaffray seek busi compani cover research report result investor awar
firm may conflict interest could affect object report investor consid report
singl factor make invest decis report read conjunct import disclosur inform
includ attest regul analyst certif found page report follow site
page
approv come
label come
fda commit reduc risk product remain clear dr gottlieb indic
intent tri transit smoker quickli combust tobacco onto reduced-risk
product made distinct combust nicotin clear nicotin
complet benign substanc isnt caus death diseas associ
tobacco use combust associ toxin consid posit iqo
approv prospect especi given flavor profil iqo typic tobacco flavor
tobacco menthol tobacco aerosol sourc believ increas
appeal smoker decreas appeal youth posit regulatori outlook
begin august end requir two primari panel cover
warn label bigger cigarett focu addict
nicotin warn begin product contain nicotin may help address
concern user specif youth unawar nicotin end one
risk howev confus around nicotin effect public believ nicotin
caus cancer fda indic effort underway chang mispercept
page
excis tax rev
good
cog percent sale
net incom attrib noncontrol int
net incom attrib altria
earn attribut share-bas award
current disclosur inform compani found www piperjaffray com/researchdisclosur
